Rocket Lab USA, Inc. (RKLB.NASDAQ) AI OPINIONS & ADVISOR ANALYSIS

The bull case activates when Neutron reaches orbit and a defence prime award lands in the same twelve months. A successful debut validates $360M-plus of programme spend, converts the Kepler manifest into recognised revenue, and lets the market underwrite medium-lift share capture against a capacity-constrained market. Iridium's cash flow simultaneously turns consolidated free cash flow positive, removing dilution risk. Scarcity value then compounds on rising estimates rather than on hope, and the shares clear their prior highs decisively.

The bear case activates if Neutron fails on debut while Iridium's subscriber base starts leaking to direct-to-device competitors. Without launch validation, investors mark the franchise to Electron's roughly $45M quarterly run-rate; without Iridium's cash, the $1.775B term loan and continuing $400M annual burn force equity issuance into a falling market. That reflexive loop, dilution begetting weakness begetting more dilution, compresses the multiple toward peers rather than legends, and the shares would more than halve.

The consensus treats Rocket Lab as "the second space company" and assumes scarcity value settles the valuation question. Sell-side framing, including Raymond James's Outperform and $80 target [22], anchors on backlog growth and the Iridium cash bridge while quietly deferring Neutron's date. The anchoring bias is the 52-week high of $99.58 [25]: a 35% drawdown feels like a discount, though 52.9x TTM sales with minus $398M free cash flow is not.

The crowd overestimates these shares, though less egregiously than six months ago. Two overlooked items: Launch Services revenue actually fell roughly 4% year over year to $44.6M in Q2 2026 [2], so the "launch company" premium rests on a shrinking line; and the Iridium purchase imports a narrowband franchise into the path of LEO direct-to-device substitution. The acquisition genuinely fixes the cash-flow hole, which is why the gap is a valuation gap, not a solvency one. Growth is real; the multiple pre-books a decade of it.

The Iridium close in mid-2027 is the catalyst, because it forces investors to value a consolidated income statement rather than a story. The first observable sign of repricing is the first combined quarter showing positive adjusted EBITDA alongside disclosed Iridium subscriber and ARPU trends, likely late 2027.